Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th
Rhea-AI Summary
Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutics manufacturing, has scheduled its fourth quarter and fiscal year 2024 financial results announcement for February 27, 2025, after market close. The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss financial results and provide a business update.
The webcast will be available on the Codexis Investor Relations website and archived for 90 days. Investors can access the live call by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A 48-hour telephone replay will be available at 877-660-6853 (domestic) or 201-612-7415 (international) with access ID #13726635.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CDXS gained 5.12%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the fourth quarter and fiscal year 2024 on Thursday, February 27, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
FAQ
When will Codexis (CDXS) report Q4 and FY 2024 earnings?
How can investors access the Codexis (CDXS) Q4 2024 earnings call?
How long will the Codexis (CDXS) Q4 2024 earnings webcast be available?
What is the replay access ID for Codexis (CDXS) Q4 2024 earnings call?
